Triple-negative breast cancer (TNBC) shows a very bad prognosis, even in early stages of disease.Metronomic chemotherapy refers\nto the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen with no prolonged\ndrug-free breaks that leads to antitumor activity. In the present article, we review preclinical and clinical data of metronomic\nadministration of chemotherapy agents with or without biological agents in TNBC cell lines and patients, contextually reporting\ndata from the VICTOR-2 study in the subgroup of patients with TNBC, in order to stimulate new ideas for the design of clinical\ntrials in this subset of patients.
Loading....